I distinctly remember the ‘it’s the data’ ‘it the science’ Weasel on TV the day he glorified Remdesivir. Oh look, we have a drug that is very effective. My group authorized a study of Remdesivir, a highly powered randomized placebo-controlled trial with about a thousand ninety plus individuals. It was an international study with sites ar…
I distinctly remember the ‘it’s the data’ ‘it the science’ Weasel on TV the day he glorified Remdesivir. Oh look, we have a drug that is very effective. My group authorized a study of Remdesivir, a highly powered randomized placebo-controlled trial with about a thousand ninety plus individuals. It was an international study with sites around the world. The end point was the time to recovery. We have a ‘data safety monitoring board’ that looks at the data, they are independent so there is no prejudice. The Board notified me and the study teams around the world on April xx that the data shows it has a significant, positive effect in diminishing the time to recover. It also trended for less deaths than in the placebo group, 8% to 11%. We are making the announcement now because whenever you have clear cut evidence a drug works you have an ethical obligations to let those in the placebo group know they can have access . . . .
[And on the other hand, when you have fact based evidence that patients get better with repurposed drugs you have an obligation to stop the use of such drugs until the Weasel finds a randomized, double blind, placebo-controlled trial with 100% effective results …]
I distinctly remember the ‘it’s the data’ ‘it the science’ Weasel on TV the day he glorified Remdesivir. Oh look, we have a drug that is very effective. My group authorized a study of Remdesivir, a highly powered randomized placebo-controlled trial with about a thousand ninety plus individuals. It was an international study with sites around the world. The end point was the time to recovery. We have a ‘data safety monitoring board’ that looks at the data, they are independent so there is no prejudice. The Board notified me and the study teams around the world on April xx that the data shows it has a significant, positive effect in diminishing the time to recover. It also trended for less deaths than in the placebo group, 8% to 11%. We are making the announcement now because whenever you have clear cut evidence a drug works you have an ethical obligations to let those in the placebo group know they can have access . . . .
[And on the other hand, when you have fact based evidence that patients get better with repurposed drugs you have an obligation to stop the use of such drugs until the Weasel finds a randomized, double blind, placebo-controlled trial with 100% effective results …]